There is provided a porous double-network hydrogel comprising: a first network comprising a first polymer; a second network comprising a second polymer. The porous double-network hydrogel comprises pores having a diameter of at least 1 μm, and the porous double-network hydrogel is perfusable and injectable.

The present invention relates to cross-linked polymers (e.g., hydrogels) including hyaluronan polymer and multimeric cross-linker for treating disorders (e.g., retinal detachment or osteoarthritis), for use in screening models (e.g., in vitro cell culture system), or for cell transplantation (e.g., in vivo cell delivery).

A method for preparing a chemiluminescent hydrogel is disclosed, belonging to the field of luminescent materials. The method for preparing a chemiluminescent hydrogel includes the steps of: slowly adding chitosan to an acetic acid solution, stirring at room temperature until completely dissolved, adding a cobalt chloride solution, followed by a polyvinyl alcohol (PVA) solution, sufficiently stirring, ultrasonically defoaming, and subjecting a resulting mixture to an alkaline bath treatment with an alkaline solution, adding N-(4-aminobutyl)-N-ethylisoluminol (ABEI), and stirring with a hydrogen peroxide solution to obtain the chemiluminescent hydrogel. The synthesized hydrogel has the advantages of high luminous intensity and long duration. In the process, a high-water-cut polymer with a three-dimensional network structure obtained by chemical crosslinking with the addition of PVA features excellent biocompatibility, high elasticity, and nontoxicity, and is one of biomedical materials with application potential.

A hydrogel product is comprising a chondroitin, molecule selected from the group consisting of chondroitin and chondroitin sulfate as the swellable polymer, wherein the chondroitin molecule is cross-linked into a network via its carboxyl groups. The hydrogel product can be prepared by a process comprising the steps of (a) providing chondroitin molecules; (b) activating the carboxyl groups on the chondroitin molecules with a triazine-based coupling reagent to form an activated, cross-linked chondroitin; and (c) cross-linking the activated chondroitin molecules via their carboxyl groups using a cross-linking agent. The hydrogel product is useful for treatment of soft tissue disorders.

The method, characterized in that, the powdered chitosan is dissolved in water to obtain a 5% solution, into which a 70-90% acetic acid is added and after the formation of the blank intramedullary nail and carrying a coagulating bath and neutralization bath it is subjected to a crosslinking bath in a solution formed from 0.5 to 2% of sodium tri-polyphosphate and 0.5% to 3% Na3PO4 for 24 to 48 hours in temperature of 50° C. to 140° C. and then it is subjected to the drying process, for a period of 6 to 10 days, and finally the surface of the blank is treated to form the intramedullary nail. The surface treatment is carried out until the surface of the intramedullary nail contains at least 20%-40% of the pore of the depth of 0.1 mm to 1 mm.

The present invention relates to a process for preparing a crosslinked gel of at least one polysaccharide or a salt thereof, comprising at least the steps consisting in: a) providing a solution formed from an aqueous medium comprising at least said polysaccharide(s) or a salt thereof in a non-crosslinked form, at least one difunctional or multifunctional epoxide crosslinking agent chosen from butanediol diglycidyl ether, diepoxyoctane, 1,2-bis(2,3-epoxypropyl)-2,3-ethylene, and mixtures thereof, and at least one phosphate salt; b) crosslinking the solution from step a) and, where appropriate; c) recovering said crosslinked gel formed.

The present invention provides crosslinking pairs of hydrogel precursor polymers, dynamic covalent hydrogels prepared from such crosslinking pairs of hydrogel precursors, pharmaceutical compositions comprising such precursors or hydrogels and uses thereof in a variety of applications.

The present invention provides a temperature sensitive hydrogel composition including a nucleic acid and chitosan. Since the hydrogel has excellent biocompatibility and biostability, and simultaneously has sol-gel phase transition properties depending on temperature changes, the hydrogel is present in a sol state at room temperature and becomes a gel when the hydrogel is injected into the human body or applied on the surface of epithelial skin and the temperature increases. Thus, the temperature-sensitive hydrogel of the present invention can be directly injected into and applied on certain parts requiring treatment and the retention and attaching time of a drug is increased through gelation depending on the temperature so that drug efficacy is sufficiently exhibited. Therefore, it is expected that the temperature-sensitive hydrogel of the present invention can be utilized for various treatments.

Closed cell chitin foam is provided. The closed-cell chitin foam composition does not absorb water, is biodegradable, and is mechanically characterized by a density range of 16 to 800 kg/m3, closed-cell pore sizes ranging from 50 microns to 1 mm, an elastic modulus of 3 to 175 MPa, and a tensile strength of 0.15 to 6.5 MPa. The chitin is at least 70% acetylated. In one aspect, the foam is enclosed in a shell e.g. in the form of a surfboard. Chitin foam according to this invention is fully biodegradable. The chitin foam overcomes the current problems with foams that contain polyurethane and polystyrene, and which are manufactured from petroleum-based sources. Petroleum based foams are not renewable, have an adverse impact on our environment, and pose significant health hazards to those who manufacture them. The chitin foam with its water-based manufacturing process and naturally sourced chitin, solves these problems.

The present invention relates to polymer compounds containing hemp and methods for producing such polymer compounds. More specifically, the invention relates to such hemp-containing polymer compounds containing one or more property-enhancing additives.